HDAC11 and central nervous system cancer: Consistent with the earlier results and assumption, the OS-oriented survival analysis in both the GEPIA (n = 676) and the CGGA (n = 404) showed that HDAC1 overexpression (GEPIA, HR:3.9, p < 0.0001; CGGA, p < 0.0001) brought risks to glioma patients (Figures 5A, 6A), while HDAC11 served as a favorable prognostic indicator (GEPIA, HR:0.37, p = 2.1e−14; CGGA, p < 0.0001) (Figures 5C, 6C).